Cory Kasimov
Stock Analyst at Evercore ISI Group
(3.65)
# 259
Out of 4,479 analysts
36
Total ratings
57.5%
Success rate
26.69%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: In-Line | $120 | $117.07 | +2.50% | 3 | Jun 27, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $53.25 | +59.62% | 1 | May 14, 2024 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $50 | $24.91 | +100.72% | 1 | May 14, 2024 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $175 | $137.49 | +27.28% | 1 | May 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $1,044.66 | +10.08% | 3 | May 14, 2024 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $113 | $82.22 | +37.44% | 3 | May 14, 2024 | |
| BNTX BioNTech SE | Initiates: In-Line | $100 | $78.76 | +26.97% | 2 | May 14, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $84 → $88 | $40.96 | +114.84% | 4 | Feb 27, 2024 | |
| CERE Cerevel Therapeutics Holdings | Initiates: Overweight | $50 | $41.23 | +21.27% | 1 | Jan 5, 2022 | |
| BIIB Biogen | Maintains: Neutral | $324 → $276 | $228.82 | +20.62% | 2 | Dec 21, 2021 | |
| SANA Sana Biotechnology | Initiates: Neutral | n/a | $5.35 | - | 1 | Mar 1, 2021 | |
| BLUE bluebird bio | Downgrades: Neutral | n/a | $0.92 | - | 1 | Feb 17, 2021 | |
| INCY Incyte | Downgrades: Neutral | n/a | $59.02 | - | 2 | May 6, 2020 | |
| GILD Gilead Sciences | Downgrades: Neutral | n/a | $68.40 | - | 1 | May 1, 2020 | |
| ALKS Alkermes | Downgrades: Neutral | n/a | $24.19 | - | 2 | Feb 14, 2020 | |
| PBYI Puma Biotechnology | Maintains: Underweight | n/a | $3.10 | - | 4 | Nov 2, 2018 | |
| AMGN Amgen | Maintains: Neutral | n/a | $310.77 | - | 2 | Jul 27, 2018 | |
| LXRX Lexicon Pharmaceuticals | Maintains: Underweight | n/a | $1.60 | - | 1 | Feb 14, 2018 | |
| DVAX Dynavax Technologies | Maintains: Neutral | n/a | $11.08 | - | 1 | Feb 14, 2018 |
Moderna
Jun 27, 2024
Maintains: In-Line
Price Target: $120
Current: $117.07
Upside: +2.50%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $53.25
Upside: +59.62%
BridgeBio Pharma
May 14, 2024
Initiates: Outperform
Price Target: $50
Current: $24.91
Upside: +100.72%
Neurocrine Biosciences
May 14, 2024
Initiates: Outperform
Price Target: $175
Current: $137.49
Upside: +27.28%
Regeneron Pharmaceuticals
May 14, 2024
Initiates: Outperform
Price Target: $1,150
Current: $1,044.66
Upside: +10.08%
BioMarin Pharmaceutical
May 14, 2024
Initiates: Outperform
Price Target: $113
Current: $82.22
Upside: +37.44%
BioNTech SE
May 14, 2024
Initiates: In-Line
Price Target: $100
Current: $78.76
Upside: +26.97%
Ultragenyx Pharmaceutical
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $40.96
Upside: +114.84%
Cerevel Therapeutics Holdings
Jan 5, 2022
Initiates: Overweight
Price Target: $50
Current: $41.23
Upside: +21.27%
Biogen
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $228.82
Upside: +20.62%
Sana Biotechnology
Mar 1, 2021
Initiates: Neutral
Price Target: n/a
Current: $5.35
Upside: -
bluebird bio
Feb 17, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.92
Upside: -
Incyte
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $59.02
Upside: -
Gilead Sciences
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $68.40
Upside: -
Alkermes
Feb 14, 2020
Downgrades: Neutral
Price Target: n/a
Current: $24.19
Upside: -
Puma Biotechnology
Nov 2, 2018
Maintains: Underweight
Price Target: n/a
Current: $3.10
Upside: -
Amgen
Jul 27, 2018
Maintains: Neutral
Price Target: n/a
Current: $310.77
Upside: -
Lexicon Pharmaceuticals
Feb 14, 2018
Maintains: Underweight
Price Target: n/a
Current: $1.60
Upside: -
Dynavax Technologies
Feb 14, 2018
Maintains: Neutral
Price Target: n/a
Current: $11.08
Upside: -